CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 60.02% | -8.98% | -26.46% | -47.61% | -52.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.94% | 0.26% | -38.86% | -61.92% | -78.92% |
| Operating Income | -120.94% | -0.26% | 33.30% | 53.42% | 71.91% |
| Income Before Tax | -105.84% | -24.44% | 28.63% | 54.83% | 81.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.84% | -24.44% | 28.63% | 54.83% | 81.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.84% | -24.44% | 28.63% | 54.83% | 81.42% |
| EBIT | -120.94% | -0.26% | 33.30% | 53.42% | 71.91% |
| EBITDA | 20.38% | 50.43% | 54.51% | 60.94% | 75.86% |
| EPS Basic | 86.36% | 76.60% | 75.14% | 76.96% | 85.59% |
| Normalized Basic EPS | 85.71% | 76.27% | 67.44% | 71.43% | 75.58% |
| EPS Diluted | 86.36% | 76.60% | 75.14% | 76.96% | 85.59% |
| Normalized Diluted EPS | 85.71% | 76.27% | 67.44% | 71.43% | 75.58% |
| Average Basic Shares Outstanding | 2,265.64% | 1,464.89% | 755.71% | 199.26% | 21.08% |
| Average Diluted Shares Outstanding | 2,265.64% | 1,464.89% | 755.71% | 199.26% | 21.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |